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1. Introduction
The goal of this consensus initiated by the European Crohn's and 
Colitis Organisation (ECCO) was to establish European consensus 
guidelines for the surgical treatment of ulcerative colitis. The strategy 
to reach the consensus involved several steps and follows the standard 
operating procedures for consensus guidelines of ECCO. An open call 
for chairs and participants for this consensus was made (see acknowl-
edgements and www.ecco-ibd). Participants were selected by the 
Guidelines' Committee of ECCO (GuiCom) on the basis of their pub-
lication record and a personal statement. Four working groups (WGs) 
were formed: WG 1 on the preoperative phase, WG 2 on the intraop-
erative phase, WG 3 on the postoperative phase and WG 4 on special 
situations. Participants were asked to answer relevant questions on 
current practice and areas of controversy related to the surgical treat-
ment of ulcerative colitis based on their experience as well as evidence 
from the literature (Delphi procedure).1 In parallel, the WG members 
performed a systematic literature search of their topic with the appro-
priate key words using Medline/PubMed/ISI/Scopus and the Cochrane 
database, as well as their own files. Provisional guideline statements 
(with supporting text) were then written by the WG chairs based upon 
answers to the questionnaire and were circulated among the WG 
members, prompting discussions and exchange of literature evidence. 
The proposed statements and the supporting text were submitted to 
an online platform for online discussion and two online voting proce-
dures among all Consensus participants for the first voting procedure 
and also for all national representatives of ECCO for the second vot-
ing procedure. The WGs finally met in Belgrade on September 25th 
2013 for a final face-to-face discussion and to vote and consent on 
the statements. Technically this was done by projecting the statements 
and revising them on screen until a consensus was reached. Consensus 
was defined as agreement by more than 80% of participants, termed a 
Consensus Statement and numbered for convenience in the document. 
The level of evidence was graded according to the Oxford Centre for 
Evidence-Based Medicine 2011 Levels of Evidence (http://www.cebm.
net/mod_product/design/files/CEBM-Levels-of-Evidence-2.1.pdf). The 
final manuscript was written by the WG chairs (WB, GS, AS, AD'H) 
in conjunction with the WG members and revised for consistency by 
T.Ø. This consensus guideline will be published in JCC and posted on 
the websites of ECCO. An update of the current guideline is planned in 
about 4 years. The European Society for Coloproctology has endorsed 
the process of producing this consensus.
The surgical treatment of ulcerative colitis was covered in the 
Second European evidence-based consensus on the diagnosis and man-
agement of ulcerative colitis Part2: Current management, published in 
JCC 2012. However it was felt that the content lacked some surgi-
cal depth and practical advice thus this first consensus on the surgi-
cal management of UC has been produced under the leadership of 
Surgical-ECCO. The present document is to be seen as complementary 
to the surgical section published in the 2012 consensus. Some consen-
sus statements are modified or expanded and others are entirely new. 
The section on pouchitis is not further elaborated here since the 2012 
consensus covers this topic adequately. Apart from this the present 
document can be read as a stand alone document on surgical aspects 
of ulcerative colitis. However reading this surgical consensus in con-
junction with the previous ECCO consensus documents on Ulcerative 
colitis will give a more comprehensive understanding of the diagnosis 
and treatment of the disease.
Development of IBD surgery as a surgical specialization has been 
rapid driven by its multidisciplinary complexity. We have seen the 
emergence and establishment of laparoscopic techniques, recently 
expanding to the use of “robots” and single port access. New variants 
of natural orifice surgery such as the Trans Anal Minimal Invasive 
Surgery (TAMIS) for proctectomy with or without an anastomosis are 
being explored and developed. These latter innovative techniques are 
not covered in this consensus since they are still at an early develop-
ment stage. Parallel to this is an ever expanding range of innovative 
new instruments allowing us to operate more effectively and hope-
fully safer. The development of guidelines and consensus in IBD sur-
gery is hampered by a lack of robust evidence in terms of randomized 
studies. Furthermore one of the main outcome variable in surgery, the 
surgeons themselves is seldom included in the evaluation of different 
methods and approaches. Thus the evidence base from which to draw 
conclusions is rather soft and this current situation is reflected in the 
views of the panelists and their interpretation of the literature.
2. Pre-operative phase
2.1 Indications for surgery
2.1.1 Acute severe ulcerative colitis
Acute severe ulcerative colitis is a potentially life-threatening con-
dition.2,3 Patients with acute severe colitis should be admitted to the 
hospital for appropriate investigation, close monitoring, and inten-
sive treatment under the care of a multidisciplinary team including 
a specialist gastroenterologist and colorectal surgeon. The simplest, 
best validated and most widely used index for identifying severe UC 
remains that of Truelove and Witts4: any patient who has a bloody 
stool frequency ≥6/day and a tachycardia (>90bpm), or temperature 
>37.8°C, or anaemia (haemoglobin b10.5g/dL), or an elevated ESR 
(>30mm/h) has severe ulcerative colitis. Only one additional crite-
rion in addition to the bloody stool frequency ≥6/day is needed to 
define a severe attack.5 The therapeutic approach to these patients is 
elaborated in Statement 5D of the second European evidence-based 
consensus on the diagnosis and management of ulcerative colitis.6 
From the surgical standpoint, it is important to emphasize the need 
for proper intravenous fluid and electrolyte replacement, nutritional 
support if the patient is malnourished, and blood transfusion to 
maintain haemoglobin above 8–10g/dL. All patients admitted with 
severe colitis require appropriate investigations to confirm the diag-
nosis and exclude enteric infection including flexible sigmoidoscopy 
and biopsy to confirm the diagnosis and exclude cytomegalovirus 
and other infections.
2.1.2 Joint treatment
A multidisciplinary approach between the gastroenterologists 
and surgeons (preferably colorectal surgeon) looking after the 
patient is essential.6 At hospital admission the surgeon should be 
promptly contacted, and the patient should be informed about 
surgical options in case of medical treatment failure. During hos-
pital stay, the patient will be best managed with a multi-disci-
plinary clinical approach. Symptoms, physical examination and 
blood tests should be closely monitored to detect signs of sys-
temic toxicity early. An objective evaluation of disease together 
with abdominal examination findings and toxicity parameters 
should be used in the decision-making process. Should any clini-
cal deterioration in patients symptoms, abdominal examination 
findings or toxicity appear during intravenous immunosuppres-
sive therapy, a prompt emergent colectomy should be considered. 
Complications such as perforation, toxic megacolon and severe 
gastrointestinal haemorrhage should equally prompt immediate 
colectomy.
Intravenous corticosteroids remain the mainstay of conventional 
therapy.6,7 Corticosteroids are generally given intravenously using 
methylprednisolone 60mg/24h or hydrocortisone 100mg four times 
daily.6 The most recent ECCO guidelines6 should be followed in 
regard to medical management.
Subcutaneous prophylactic heparin or low molecular weight heparin 
is indicated to reduce the risk of venous thromboembolic events (VTE) 
which has been shown to be increased in patients with IBD compared to 
controls, especially during a disease flare.8 Prophylactic VTE treatment 
should be withheld only in patients with severe lower intestinal bleeding.
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Prolonged intravenous immunosuppressive therapy is associated 
with increased morbidity and mortality following subsequent sur-
gery.9,10 In addition, extending intravenous corticosteroids therapy 
beyond 7 to 10days carries no additional benefit.5 For this reason, 
response to treatment should be evaluated early in the course of 
first-line treatment with i.v. corticosteroids, around the third day of 
treatment.6 Simple, objective measures are needed to aid decision-
making. Clinical markers such as stool frequency and body tempera-
ture, biological markers such as CRP, erythrocytes sedimentation 
rate, and radiographic and endoscopic appearance can be used to 
predict response. The correlation between these signs and the chance 
of colectomy is elaborated in recommendation 5F of the second 
European evidence-based consensus on the diagnosis and manage-
ment of ulcerative colitis.6 These objective measures should aid the 
sound clinical judgment of an IBD gastroenterologist jointly with a 
colorectal surgeon. It is important to ensure that the surgical options, 
as well as the therapeutic alternatives for second line rescue of ster-
oid refractory disease (cyclosporine, tacrolimus, and infliximab) are 
considered early (on or around day 3 of corticosteroid therapy), since 
a delay in the decision making process, with patients remaining on 
ineffective medical therapy, results in a higher surgical morbidity.9,10
Infliximab has been shown to be an effective salvage therapy in 
patients with severe UC refractory to iv corticosteroids.11,12 Cyclosporine 
has also been shown to be effective second line therapy in the treatment 
of severe UC.12,13 When considering the use of cyclosporine in patients 
with acute severe colitis despite treatment with an appropriate dose 
of immunomodulation such as thiopurine, it is important to consider 
whether there are options for long term maintenance of remission.
In case of no improvement with second line therapy, colectomy 
is generally recommended to avoid further increase in surgical mor-
bidity and potential mortality.9,10 Randall et  al.10 retrospectively 
reviewed a prospectively maintained database of patients who under-
went surgery for acute severe ulcerative colitis. On multivariate anal-
ysis, only duration of in-hospital medical treatment was associated 
with increased rate of postoperative complications with odds ratio 
of 1.12 (CI 1.00 – 1.24). Maser et al.9 reported 10% mortality in a 
small group of 10 patients receiving third line of immunosuppres-
sion following failure of both intravenous corticosteroids and second 
line “salvage” treatment. In light of the current literature, colectomy 
should be strongly recommended in case of failure of a second line 
medical treatment within the timeframe of seven days. Reports of 
success of a third line immunosuppressive therapy14 should be bal-
anced against potential risks of these treatments, bearing in mind that 
acute severe colitis is a potentially life threatening disease. In light 
of the current literature, third line intravenous immunosuppressive 
treatment should be reserved for highly selected cases, after careful 
discussion between the patient, gastroenterologist and colorectal sur-
geon, in a specialist referral centre, preferably within a clinical trial.
2.1.3 Chronic refractory ulcerative colitis
In elective situations (often in refractory colitis, chronically 
active despite optimal medication regimen, or corticosteroid 
dependent disease) the time lag between the decision for surgery 
and the procedure itself is usually several weeks, and depends on 
clinical practice and a variety of different factors. The patient's gen-
eral condition, including nutritional status and the use of immuno-
suppressive medications is of great importance not only regarding 
surgical results and complication rate, but also for the decision on 
surgical strategy (restorative proctocolectomy with ileal pouch-
anal anastomosis versus subtotal colectomy with end-ileostomy). 
For this reason, colorectal surgeon and gastroenterologist should 
jointly make any attempt to optimize the patient's general condition 
prior to surgery, and plan the surgical procedure balancing both the 
need to treat the patient's active disease, and the need to optimize 
patient's general conditions, reducing surgical risks, as pre-oper-
ative corticosteroid and immunosuppressive therapy can impact 
postoperative complications.15,16
Weaning off corticosteroid treatment prior to surgery (provided 
that this does not result in a significant exacerbation of the inflam-
matory disease) and improvement of nutritional status, both directly 
affecting the risk of surgical complications, are determinant factors 
for surgical outcomes optimization.15,16
The effect of biologic therapies on surgical complications is still 
debated,17–19 while thiopurines do not increase the risks of surgery 
(see Statement 4D and 5).
The time lapse between indication and surgery (usually some 
weeks) can be used by the managing clinician for the gradual taper-
ing of steroid dose, but may not completely eliminate the effect of 
anti-TNF therapy on the immune response: the half-life of the anti-
body is variable,20 and duration of its immunosuppressive effects 
still remains undefined. Surgery should not be delayed in patients 
who recently received anti-TNF therapy. But in the absence of defini-
tive evidence, biologic therapy is often included among the factors 
favouring a three-step surgical approach.
2.1.4 Dysplasia/carcinoma in UC
Even if dysplasia can be divided, according to the grade of neo-
plastic change, into 3 morphologic categories (indefinite, low grade-
LGD, or high grade-HGD),21 it is accepted that it evolves along a 
progressive (continuous) scale rather than in discrete categories. 
There is a significant interobserver variability in interpretation of the 
presence and the grade of dysplasia even among experienced gastro-
intestinal pathologists,22,23 given the chronic inflammatory changes 
in the mucosa and the effect of concomitant medical therapies. Such 
limitations in the assessment of dysplasia have led to the recommen-
dation that histological slides should be reviewed by a second expert 
gastrointestinal pathologist, prior to any surgical decision.6
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In three studies including a limited number of cases with HGD 
(from 6 to 24 patients) flat HGD dysplasia is associated, in 42–67% 
of cases, with synchrounous concomitant colorectal cancer (CRC).24–
26 In a review of collected data from prospective surveillance trials: 
15 of 47 patients (32%) with HGD developed CRC upon further 
follow-up.24 Data from the St Mark's surveillance programme con-
firmed the risk, since 2 of 8 patients (25%) with HGD without colec-
tomy progressed to CRC).27 Overall, the immediate and subsequent 
risk of CRC in patients with flat HDG is large enough to warrant a 
recommendation for colectomy.6
Indications for the management of flat LGD in UC are less clear 
than for HGD: many studies do not report the outcome of LGD 
distinguishing between raised and flat lesions.
In three studies with a small number of patients operated on for 
LGD (n=10, 11, 16) 20%, 27% and 19% of the patients, respec-
tively, were found to have CRC.24,26,27 In a meta-analysis of 20 stud-
ies, for patients with LGD detected on surveillance, the overall risk 
of developing CRC was increased 9-fold and the risk of developing 
CRC or HGD was increased 12-fold.28 In this same meta-analysis, 
the positive predictive value for progression from LGD to HGD or 
CRC was 14.6%.28 High rates of progression have generally been 
reported in retrospective studies.26,29 In contrast, prospective studies 
reported no increased progression rates in patients with LGD com-
pared to patients without dysplasia.30,31
In conclusion, although the rate of synchronous CRC is lower for 
LGD than HDG, it is still considerable. The current evidence is insuf-
ficient to assess the balance of risks and benefits of colectomy for 
flat LGD. Thus, the decision to undergo colectomy versus continued 
surveillance in patients with flat LGD should be individualised and 
carefully discussed between the patient, the gastroenterologist and 
the colorectal surgeon. Colectomy will eradicate the risk of CRC, 
but if a patient, correctly informed about the risks, is unwilling to 
undergo colectomy, tight surveillance is strongly recommended.32
Raised lesions with dysplasia in colonic segments affected by UC can be 
macroscopically divided into those resembling non-IBD-related sporadic 
adenomas (adenoma-like raised lesions) and those, which do not appear 
like sporadic adenomas (non-adenoma-like raised lesions). Regardless, all 
raised lesions should be completely endoscopically resected whenever pos-
sible and the surrounding area should undergo biopsy: surgery should be 
considered if dysplasia is present in the surrounding mucosa or if the mass 
cannot be completely resected.6 Polyps in colonic segments proximal to 
UC involvement should be treated as sporadic adenomas.
In patients with a preoperative diagnosis of dysplasia/cancer proc-
tocolectomy should include oncologic lymphadenectomy with ligation 
of the vessels at their origins. Restorative surgery is obtainable in most 
patients, while an abdomino-perineal excision with end-ileostomy is 
warranted in patients with very low rectal cancer where adequate distal 
clearance cannot be obtained or in whom the anal sphincter is damaged. 
No data support an oncologic superiority of mucosectomy over stapled 
anastomosis in the presence of dysplasia or CRC: cancers are reported 
both in patients with a stapled anastomosis as well as in those who have 
had a mucosectomy, and there is evidence that a mucosectomy does not 
necessarily clear all remnants of mucosa.33 In addition, there is evidence 
that the stapled technique is as safe under these circumstances as hand 
sewn.34–36 However it seems reasonable, when the indication for surgery 
is cancer or high grade dysplasia of the lower rectum, to perform a 
mucosectomy and anastomosis at the dentate line.
In highly selected cases of HGD or CRC located in a proximal 
colonic segment, in presence of a mild rectal disease, colectomy with 
ileorectal anastomosis may be considered, following careful discus-
sion with the patient regarding the increased risk of neoplastic trans-
formation, as high as 8.7% at 25year disease duration for ileorectal 
anastomosis compared to 1.8% for IPAA.37
2.2 Risk factors for colectomy and for post-
operative complications
2.2.1 Peroperative risk assessment
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A number of variables have been associated with a higher colec-
tomy rate in patients with ulcerative colitis (UC). Although the 
identification of early predictors of colectomy would be potentially 
useful, none of the described risk factors are currently directing 
medical therapy.
2.3 Clinical presentation
More severe disease activity,38–40 more extensive UC38,41–45 presence of 
extra-intestinal manifestations,46 a younger age at diagnosis,44,47 and 
non smoking,42,45,48–50 have all been associated with higher colectomy 
rates. Furthermore, in a North-American trial using the Nationwide 
Inpatient Sample 2004, anemia, requirement for blood transfusion, 
malnutrition, and total parenteral nutrition were independent pre-
dictors of colectomy.51
In a Belgian cohort study evaluating the efficacy of cyclosporine, 
patients refractory to azathioprine, showed a significant higher 
colectomy rate on the long-term.52 This observation was later con-
firmed in other cohort studies.53–55
2.4 Baseline serological, fecal and genetic markers
Elevated C-reactive protein, elevated fecal calprotectin, and decreased 
albumin levels have been associated with colectomy.39,43,56–59 Other 
serological markers, such as perinuclear antineutrophilic cytoplas-
mic (pANCA) and anti Saccharomyces cerevisiae antibodies (ASCA) 
have not been associated with long-term colectomy risk.57,60,61
Genetic variations in HLA, MDR1 and MEKK1 have also 
been associated with colectomy risk in UC, but are lacking 
confirmation.53,60,62
2.5 Baseline endoscopic disease activity
In the pre-biological therapy era, the IBSEN cohort demonstrated 
that patients with mucosal healing at one year had a lower risk of 
colectomy at 5years.63 In two trials evaluating the efficacy of IV 
steroids and IV cyclosporine in acute severe UC, severe endoscopic 
lesions at baseline were associated with a significantly higher colec-
tomy rate during follow-up.56,64
2.6 Short-term clinical, biological and endoscopic 
response to treatment
The well-known Oxford criteria in patients with acute severe UC 
were based on a trial evaluating predictors of bad outcome on day 
3 of IV steroid therapy.65 Of note, 85% of patients with more than 
eight stools on day 3, or a stool frequency between three and eight 
together with a CRP >45mg/l, would require colectomy. Therefore, 
rescue therapy with cyclosporine, infliximab or surgery seems war-
ranted if the Oxford criteria are met.
Several investigators showed that in outpatients with moder-
ate-to-severe UC receiving infliximab as well as in hospitalized 
patients treated with infliximab for acute severe IV steroid-
refractory UC, both clinical response and mucosal healing in 
the short-term were predictive of colectomy-free survival in the 
longer-term.39,59,66–68 Furthermore, in a Belgian cohort study, 
the absence of a normalization of CRP levels in the short-term 
(absence of biological response) was also associated with the need 
for colectomy in the longer-term.57,60 Similarly, a normalization of 
fecal calprotectin levels (≤100μg/g) after induction therapy with 
anti-TNF agents was predictive of sustained clinical remission 
after one year, but an influence on colectomy-free survival was 
not reported.59
2.7 Serum levels
Higher IFX serum levels have been associated with a better long-
term outcome of IFX treated patients, including lower colectomy 
rates.69 A recent Belgian study, demonstrated that serum IFX levels 
≥3μg/mL at week 14 were predictive of colectomy-free survival.57
2.7.1 Risk factors for postoperative complications
Pouchitis is the most common post-operative complication in 
patients undergoing pouch surgery.70 Genetic, demographic, clini-
cal and serological risk factors for pouchitis have been exten-
sively studied. Reported risk factors for pouchitis include younger 
age at colectomy,60 smoking status,71,72 regular use of NSAIDs,71,72 
extensive ulcerative colitis,73 the presence of backwash ileitis,60,74 
and extraintestinal manifestations, particularly primary sclerosing 
cholangitis.60,75,76
Variations in TLR1, TLR9, CD14, ILR1N and NOD2 have been 
associated with the development of pouchitis.60,76,77 Seropositivity for 
pANCA,71,78,79 anti-CBir1 flagellin,78 antibodies to outer membrane 
porin,60 or chitobioside carbohydrate-specific antibodies60 seems to 
be another risk factor for pouchitis.
2.7.2 Preoperative medical therapy
There are good data suggesting that corticosteroids (CS) increases 
short-term complications after colectomy for UC. One study com-
pared patients' outcomes after colectomy in regard to the adminis-
tration of steroids, with or without concomitant azathioprine/ 6-MP. 
There was a significant higher risk of any (odds ratio=3.69) or major 
infectious complications (odds ratio=5.54) after the procedures in 
patients who were taking steroids at the time of surgery.80 Another 
study demonstrated higher incidence of postoperative infectious 
complications in patients who received a higher cumulative dose of 
steroids before they were submitted to pouch surgery.81 In a Belgian 
cohort study from, moderate-to-high dose of CS (at least 20mg 
of prednisolone at first surgery) was associated with short-term 
postoperative pouch-specific complications (OR 10.20 [95% CI: 
2.47–42.12] (p=0.001), surgical site infectious complications (OR 
7.96 [95% CI: 2.17–29.22] (p=0.002) and infectious complications 
overall (OR 5.19 [95% CI: 1.72–15.66], (p=0.003).82 These studies 
suggest that patients with corticosteroids at surgery may have lower 
complication rates with subtotal colectomy first, avoiding a pouch 
construction at the first operation.
8 T. Øresland et al.
One study from the United States demonstrated that after pouch 
surgery for UC, previous exposure (from 7 up to 30days before the 
operation) to azathioprine/ 6-MP did not affect the rates of short-
term and late postoperative complications.83 The same pattern was 
observed in the study from Aberra et al., previously discussed.80
Preoperative use of infliximab does not appear to increase the 
risk of infectious complications. There may however be an increase 
in short-term surgical complications. One retrospecive observational 
study from the Mayo Clinic (USA) demonstrated that previous (ever) 
exposure to IFX increased the rate of complications in pouch sur-
gery. In this series, they found that the IFX patients had higher risk 
of anastomotic leakage, pouch-specific and infectious complications 
than the controls. Again, IFX was identified as the only independent 
factor related to infectious complications (OR=3.5).18 Another study 
from the Cleveland Clinic (Ohio, USA) demonstrated similar results. 
They found that the odds ratio for early complications was 3.54 
(p=0.004), for sepsis was 13.8 (p=0.011) and for late complications 
was 2.19 (p=0.08). They concluded that previous (ever) IFX should 
led the patients to a 3-stage procedure regarding the high risk of 
poor outcomes.17
On the other hand, other studies revealed opposite results. 
Data from Belgium, demonstrated that high doses of steroids 
and pouch surgery without a defunctioning ileostomy, but not 
IFX (within 12weeks of surgery), were independent factors for 
higher complication rates after restorative proctocolectomy with 
ileal pouch anal anastomosis.82 Retrospective data from USA84 
and from Denmark85 (both with IFX within 12weeks of surgery) 
also concluded that IFX did not increase morbidity after surgical 
treatment for UC. The largest sample of patients studied with the 
aim of detecting the influence of IFX on surgical complications in 
UC came from Denmark, in a nationwide registration with more 
than 1200 patients that included 199 IFX (within 12weeks of sur-
gery) exposed individuals: they also found no significant increase 
in complications after surgery on the IFX previously exposed 
patients.86 A study from the Netherlands suggested that patients 
submitted to a one-stage procedure (pouch construction without 
a diverting ileostomy) had a higher rate of pelvic sepsis if they 
had previous IFX, suggesting again that in these patients a total 
colectomy with end ileostomy should be considered.87 A  meta 
analysis including most studies regarding this topic cited in this 
section demonstrated that recent or ever used IFX as an independ-
ent factor increased the rate of total postoperative complications 
(OR =1.80), but not significant if only looking at inflammatory 
complications.88
Many studies have demonstrated the advantages of enhanced 
recovery protocols after colorectal surgery, with a shorter hospital 
stay and lower overall complication rates.89 These principles can be 
applied in the surgical management of ulcerative colitis, but specific 
studies in the management of this disease are still needed.
2.8 Intraoperative phase
2.8.1 General
Laparoscopic IPAA is an appealing alternative to open surgery 
and it is performed with increasing frequency in many centers. 
Feasibility and safety of the laparoscopic technique has been shown 
in various studies.
A RCT in 2004 failed to demonstrate differences in short term 
benefit or in quality of life for laparoscopic versus open surgery.90 
However, this study only included operations, which were laparo-
scopic assisted. A second RCT designed in 2006 to compare blood 
loss and need for perioperative blood transfusion during totally 
laparoscopic versus open IPAA had severe difficulties recruiting 
patients.91 A  meta-analysis published in 2007 showed a longer 
operative time and less blood loss in laparoscopic surgery but no 
significant differences in postoperative adverse events between 
laparoscopic and open surgery.92 In 2009, a Cochrane review was 
published.93 demonstrating no difference in mortality or complica-
tions between open and laparoscopic (assisted) ileo pouch anal anas-
tomosis for ulcerative colitis and familial adenomatous polyposis. 
Operative time was longer but cosmesis better for the laparoscopic 
approach. In 2011 data from an ASCRS database were published 
reporting a significant reduction in both major and minor complica-
tions in laparoscopic IPAA.94 The laparoscopic approach was asso-
ciated with advantages including reduced intraoperative blood loss 
and earlier recovery as demonstrated by shorter length of hospital 
stay. Recently two reports on a significant better preservation of 
female fecundity after laparoscopic IPAA were published.95,96 This is 
in line with a report on a reduction in visceral and pelvic adhesions 
after laparoscopic IPAA.97
The management of the remaining rectum following colectomy 
for acute severe colitis includes three options: intra-peritoneal rec-
tal stump closure (Hartmann's pouch), creation of a mucous fistula 
by exteriorizing the rectosigmoid remnant or to position the closed 
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rectosigmoid remnant in the subcutaneous tissue in an attempt to 
prevent peritonitis in the event of a stump blow out.
Rectal stump leakage resulting in pelvic sepsis occurs in 6–12%.98 
Trans-anal drainage of the Hartmann's pouch could be considered 
to prevent acute rectal stump blowout. The creation of a mucous 
fistula (in the left iliac fossa, suprapubic or in the same opening as 
the ileostomy) necessitates a longer rectosigmoid stump.
There are no randomized studies that compare the three tech-
niques. Three retrospective studies were published. The largest com-
pared Hartmann's pouch (n=99) to subcutaneous placement of the 
closed rectal stump (n=105).99 There was no difference in pelvic sep-
sis but a significant higher wound infection rate for the last group. 
A  second study compared local and systemic morbidity related to 
the rectal stump in the three mentioned groups.98 In this study, the 
incidence of pelvic sepsis was higher in the Hartmann group (12%) 
compared to a mucous fistula or subcutaneous stump placement. 
Persistent rectal disease was more common in the Hartmann group 
and subsequent pelvic dissection was more difficult compared to the 
other two techniques. In a third study Hartmann's pouch (n=27) was 
retrospectively compared to subcutaneous stump placement (n=10) 
which resulted in 2 anastomotic leaks in the Hartmann group and 3 
secondary stump dehiscence's in the subcutaneous group.100
2.8.2 Surgical approach in urgent colectomy
The considerations below are not applicable to the emergent setting 
with an unstable patient and the results of urgent colectomy can-
not be generalized to critically ill patients in need of an emergent 
colectomy.
When an emergency colectomy for fulminant ulcerative colitis is 
necessary, it is possible to perform a laparoscopic or open colectomy. 
In a recent systematic review of laparoscopic versus open colectomy 
for non-toxic colitis, laparoscopic surgery resulted in less wound 
infections and intra-abdominal abscesses and a shorter hospital 
stay.101 However, these results may be altered in critically ill patients 
in need for an emergency colectomy.
In recent years a few studies have been published focusing on 
laparoscopic emergency colectomy in acute ulcerative colitis. The 
first study from the Mayo Clinic used a prospective database to 
determine safety, feasibility, and short-term outcomes of three-
stage minimally invasive surgery for fulminant ulcerative colitis. 
Of 50 procedures 72% was performed with laparoscopic-assisted 
and 28% with hand-assisted techniques. Completion proctectomy 
with ileal pouch-anal anastomosis was performed in 42/50 patients 
with a low conversion rate (2.3%). During the postoperative period 
there were no anastomotic leaks or mortality.102 In a second study 
short-term outcomes of laparoscopic versus open total abdominal 
colectomy and end ileostomy for severe UC were compared. Using 
a prospective database, 72 patients with fulminant ulcerative colitis 
undergoing surgery were investigated. Thirty-one patients under-
went a laparoscopic colectomy and 41 patients an open colectomy. 
The laparoscopic group had less narcotic usage, faster return of 
bowel function and shorter length of hospital stay. Furthermore the 
laparoscopic group underwent subsequent restorative proctectomy 
49days sooner and ileostomy closure 17days sooner than the open 
colectomy group.103 In a third study a retrospective analysis was 
performed to compare peri- and postoperative complications in lap-
aroscopic and open colectomies in an urgent or emergency setting. 
Of 90 patients 29 were operated laparoscopically. Laparoscopic 
subtotal colectomy was associated with improved cosmesis, reduced 
intraoperative blood loss, negligible wound complications, and 
shorter hospital stay in comparison to the open colectomy group.104 
All three studies conclude that emergency laparoscopic colectomy 
for fulminant ulcerative colitis is a safe and feasible alternative to 
open colectomy and offers some clinical benefits. However, it should 
be noted that these studies were performed in high-volume hospitals 
with significant laparoscopic and inflammatory bowel expertise.
2.8.3 Rectal dissection
Most surgeons perform a modified TME dissection today (=ante-
rolateral close rectal dissection in combination with a posterior dis-
section in the TME plane).
The main argument for close dissection is to minimize the risk of 
damage to the pelvic autonomic nerves and to better preserve sexual 
function.105–108
Sexual dysfunction affects up to 3% of men following pouch 
surgery and therefore sperm banking could be recommended.105,106 
It has also been postulated that mesorectal preservation diminishes 
septic complications.109 The idea is based on the premise the retained 
mesorectal fat would allow for better pelvic filling and reduces the 
risk of a presacral sinus if the anastomosis leaks.
2.8.4 Pouch and anastomosis
A good pouch function depends mostly on patient's sphincter 
function, pouch volume and compliance.110 Several pouch designs 
have been described: S-, J- and W-pouches.111 A meta-analysis includ-
ing 1519 patients reported no significant difference in surgical out-
come in terms of pelvic sepsis, early pouch failure or mortality.112–114 
Operating time is shorter for J-pouches. The number of bowel move-
ments tends to be higher in J-pouches, as a consequence of a smaller 
pouch volume.112,115–121 The difference in number of bowel move-
ments diminishes after longer follow up, and disappears mostly in 
long follow up series.115,119 Pouch design is therefore predominantly 
of importance during the pouch maturation period. S-pouches have 
a higher incidence of evacuation difficulties due to the longer outlet 
limb of the pouch, which frequently makes pouch intubation nec-
essary.112,113,118 All pouch offer the patient a similar ability to defer 
defeacation.114 Only very few patients experience urgency, which is 
an important drawback on quality of life.
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The retained rectal stump in a stapled anastomosis should be 
minimal (<2cm) to minimize the risk of subsequent cuffitis and or 
dysplasia at the site of the rectal remnant. It is recognized that a 
stapled anastomosis may fail technically during the procedure and 
therefore all surgeons performing pouch surgery should be compe-
tent to perform a hand-sewn endo-anal anastomosis. Mucosectomy 
and hand sewn anastomosis results in poorer continence (even at 
12months of follow-up), lower anal resting pressures and a perma-
nent loss of the recto-anal inhibitory reflex.122–125 Recovery of the 
recto anal inhibition reflex (RAIR) has been linked to less night-
time soiling.126 However all sensation levels and related pressures are 
unaffected by the recovery of RAIR.122,127
Despite the absence of clear evidence a recent survey demon-
strates that a low-stapled ileo anal-pouch anastomosis has become 
the standard of care (>95%).128
In a more recent meta-analysis including only randomized data 
no advantage in functional or manometric outcome was noted in a 
stapled anastomosis versus hand-sewn anastomosis group.129
2.8.5 Alternative procedures
Intersphincteric proctectomy (ISP) has been recommended since 
the early 60s. There is lack of randomized data (ISP versus conven-
tional proctectomy) however it appears logical to spare the pelvic 
floor and EAS (external anal sphincter) to provide optimal pelvic 
floor closure and reduce the risk of perineal wound healing prob-
lems. In1984 Zeitels et  al. and Leicester RJ et  al. recommended a 
more widespread use of the technique, as perineal healing was more 
constant.130,131 In 2000 Adam and Shorthouse recommended inter-
sphincteric dissection and selective use of omental transposition for 
optimal outcome in UC and reported no persistent perineal sinus 
(0/27 patients).132
The Kock's pouch (continent ileostomy) was devised by Nils 
Kock in 1969.133 The procedure became popular until IPAA was 
introduced in the 1980's.
Today, Kock's pouch is not an alternative to IPAA, but is an alter-
native to conventional end-ileostomy for patients with failed IPAA, 
or for those who are not candidates for IPAA (sphincter injury etc.) 
and for those who have considerable problems with an ileostomy 
(leakage, skin problems, etc.).
The Kock's pouch has been discredited by many surgeons due to 
a high reoperation rate. About half the patients will need reopera-
tion, nipple valve sliding is the most common indication. However, 
most series today have a 10year continent pouch survival around 
90%.134,135 Quality of life with a Kock's pouch seems superior to 
an end-ileostomy. According to a study from the Cleveland clinic 
patients with an end-ileostomy were more than twice as likely to 
report social, work, and sexual restrictions compared to Kock's con-
tinent ileostomy.134
The good long term functional outcome after IPAA and a rather 
unpredictable functional outcome after ileorectal anastomosis on a 
noncompliant and inflamed rectum and the subsequent fear of rectal 
cancer explains the reluctance of many surgeons to perform IRA 
for ulcerative colitis today.136 IRA consists of a less complex proce-
dure with lower morbidity rates and with reasonable clinical results 
in highly selected patients. Patients considered for IRA are usually 
those presenting with a relatively spared rectum (or a healed rectum 
under medical therapy), good rectal compliance and normal sphinc-
ter tone In these selected patients the defecation habits are almost the 
same as for the IPAA patients, however urgency is more common in 
most published series with IRA (22-33%).137,138 Urgency is the most 
common cause of failure after IRA. The reported probability of hav-
ing a functioning IRA has ranged from 74 to 84% at 10years and 
from 46 to 69% at 20years.136,137,139,140
2.8.6 Loop ileostomy
IPAA can be performed as a one, two or three stage procedure. 
In emergent conditions a total colectomy with end ileostomy will 
precede the pouch procedure. In elective cases the procedure is per-
formed either as a two (with a defunctioning ileostomy) or one stage 
procedure. The reported risk for anastomotic leakage and pelvic sep-
sis in expert centers is approximately 10%.141 Defunctioning ileos-
tomy reduces the septic consequences of leakage but also the rate of 
leakage itself. No randomized trials have been reported.
Proponents of a two-stage procedure claim a reduced morbidity 
and mortality of anastomotic leakage and pelvic sepsis.142–144 Pelvic 
sepsis not only can have immediate potential life threatening conse-
quences but also is associated with pouch dysfunction and ultimate 
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pouch failure.145 Temporary diversion results in improved physi-
ological recovery of the anal canal. Stoma closure is safe with low 
morbidity.146 Furthermore patients seem to value the advantages of 
the pouch more after having experienced an ileostomy.
Proponents of a one-stage procedure claim a reduced overall hospital 
stay and reduced morbidity (linked to an ileostomy: e.g. skin problems 
and dehydration, and linked to ileostomy closure). Diversion ileitis is 
avoided and continued use of the anal sphincter would result in bet-
ter function. Furthermore sepsis is well managed without diversion in 
majority of cases and without impact on pouch function in the long 
term.147–149
There seems to be a tendency to promote a selective approach 
based on patient characteristics, which has recently been reported in 
a 5-point nomogram.128,148,150–153 Some surgeons recommend pouch 
intubation with regular irrigation and claim the same benefits as for 
diversion but without the complications of a stoma.99
There have been several reports on risk factors for pelvic sepsis after 
IPAA: although not universally accepted most common predictors for 
morbidity are: age, male patients, preoperative corticosteroid use and 
hand sewn anastomosis. A recent meta-analysis comprising 17 reports 
and including almost 1500 patients100 (765 without ileostomy and 721 
with ileostomy) found that although anastomotic leakage was more 
common in the group without the stoma at the time of pouch surgery 
(OR: 2.37; 95% CI, 1.39–4.04; p=0.002) pouch related sepsis was not 
different for both groups. Furthermore both stricture of the pouch-anal 
anastomosis (OR, 0.31; 95% CI, 0.10–0.98;p=. 045) and pouch failure 
(OR, 0.30; 95% CI, 0.12–0.74; p=. 009) were significant reduced in the 
no-stoma group. Small bowel obstruction was more common in the 
stoma group (OR, 2.37; p=0.002).
In summary, restorative proctocolectomy for ulcerative colitis 
should be covered with a loop ileostomy especially in the presence 
of risk factors. Temporary intubation of the pouch should be consid-
ered in those selected patients with a one-stage procedure.
2.8.7 Volume of surgery
It has been demonstrated in numerous publications that volume of surgery 
and specialization has a beneficial effect on patient outcome. Recent studies 
show significantly lower mortality rates in high volume hospitals for various 
surgical procedures.154 In a 2007 systematic review the authors conclude that 
in particular high surgeon volume was associated with improved patient out-
come.155 Two studies were published that focused on learning curve in ileal 
pouch-anal anastomosis surgery and volume analysis for restorative proc-
tocolectomy. The first study used a risk-adjusted cumulative sum (CUSUM) 
model to monitor outcomes in IPAA surgery performed by 12 surgeons in a 
single center from 1983 to 2001.156 It was calculated that the learning curve 
to perform stapled IPAA surgery for trainee staff is 23 cases and for hand 
sewn IPAA surgery: 31 procedures. In a recent observational study in England, 
the effect of institutional and surgeon caseload on outcome following pouch 
surgery was analyzed.157 Thirty percent of institutions performed less than 
2 procedures a year and 91.4% performed 20 or fewer procedures during 
8years. High-volume centers (>8.4 procedures annually) reported significant 
less pouch failure than mid- and low-volume centers.
2.9 Postoperative phase
2.9.1 Risks and complications
Emergency colectomy for acute colitis in ulcerative colitis is 
associated with a mortality rate of 5–8% and morbidity rates of 
27–51%.158,10,159,160 Higher mortality rates are to be expected when 
the colon is perforated.161 Risk factors increasing morbidity are 
prolonged conservative treatment and hospitalization prior to sur-
gery10,162 advanced age and co-morbidity.163 According to the system-
atic review158 the most frequent complications are wound infection 
(18.4%), intra-abdominal abscess (9.2%), small bowel obstruc-
tion (6.2%), ileostomy related complications (5.5%), hemorrhage 
(4.6%). Septicemia was observed in 18% of the patients, pneumonia 
in 11%, thromboembolic complications in 7.2%, pulmonary embo-
lism in 7% of patients. In a systematic review abdominal abscesses 
are reported at a frequency of 3.4% and 12.6% after a laparoscopic 
and open emergency colectomy respectively.101 A  publication bias 
might explain the favourable results.
Mortality after elective IPAA is rare (0–1%). Postoperative com-
plications are high though. The incidence of early postoperative com-
plications in a high volume center was 33.5% in a large retrospective 
study (3707 patients).70 More recent metaanalysis show a tendency 
to a decrease in pouch failure rate and pelvic sepsis rate (4.3% 
resp. 7.5%)164 which might reflect surgery in more specialised centers.
Weston et al. meta-analysed the leak rate of restorative procto-
colectomy with or with an ileostomy.151 The leakage rate was dimin-
ished but not abolished by a covering ileostomy (4.3% versus 9.3%, 
OR, 2.37; 95% CI, 1.39–4.04; P=.002). The routine creation of an 
ileostomy after restorative proctocolectomy is adopted by most colo-
rectal surgeons because it may reduce the disastrous clinical con-
sequences of leakage.165,166 Moreover pelvic sepsis has a significant 
negative impact on long term pouch function and is correlated with 
long term failure rate. However the lower leakage rate of an ileoanal 
anastomosis covered by an ileostomy must be balanced against the 
morbidity and mortality of the creation and closing of an ileostomy. 
(L3a, RG C). In almost all cases a leaking anastomosis must be 
defunctioned if not done so at the initial procedure.167,168
After restorative proctocolectomy overall incidence of SBO var-
ies between 13–30% and increases with length of follow up.169–173 
Most events are treated conservatively, but up to 25% of patients 
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need surgical treatment.170 Ileostomy increases the risk of SBO events 
and frequency of surgical treatment. Laparoscopy didn't decrease 
the number of SBO episodes.169
Patients suffering from UC are at increased risk of thromboem-
bolic events.174–177 In a large review of US surgical patients the inci-
dence was 3.3%. They were at higher risk of death (4% vs. 0.9%).176
Postoperative bleeding from the IPAA is rare (1.5%), but if it 
happens, it is mainly caused by bleeding at the staple line.178 Pouch 
suture line inspection immediately after creation may prevent post-
operative bleeding. Postoperative treatment is usually conservative 
and consists of evacuation of clots, epinephrine enema, hemostatic 
treatment through pouchoscopy. Early postoperative ischemia of 
IPAA is rarely reported in the literature. It could lead to leak or sepa-
ration of ileo-anal anastomosis or abdominal sepsis.170 It occurs in 
up to 4.3% in some series. Ischemia could be created by tension of 
the ileocolic pedicle, thrombosis of ileocolic artery or volvulus.179,180 
Pouchoscopy and CT angiography are the main diagnostic proce-
dures. Well timed pouch extirpation is warranted in case of pouch 
necrosis. Volvulus of the pouch might be a one of the causes of 
ischemia. Immediate derotation and fixation is necessary.
2.9.2 Loopileostomy closure
Loop ileostomy closure is typically undertaken 8–12 week after 
construction allowing sufficient time for recovery from the initial 
resection. Loop ileostomy closure can have significant impact on the 
patient with morbidity rate of up to 33%.168 In a recent systematic 
review the reported rates of small bowel obstruction following loop 
ileostomy closure was 7.2%, 1/3 of them required re-laparotomy, 
anastomotic leak rates were 1.4%, enterocutaneous fistula 1.3%, 
wound infections 5.0%, and stoma site hernias 1.3%.167
Loop ileostomy closure after laparoscopic colorectal surgery is 
associated with a significantly shorter operative time and hospital 
stay, as well as with lower rates of postoperative complications than 
after open surgery.181 Ileostomy closure can be performed using 
either a stapled or a sutured technique and although opinion differs 
as to the optimal closure technique a recent meta-analysis revealed 
no significant differences in short-term outcome between the two 
approaches.182 Early closure (within 2weeks) of a covering ileostomy 
is an option if imaging has shown an intact anastomosis.183,184 A con-
trast enema before closure is common practice to rule out silent 
anastomotic leaks before closure.185
2.9.3 Follow-up
The prevalence of high-grade dysplasia, low-grade dysplasia and 
indefinite for dysplasia was 0.15 (range 0–4.49), 0.98 (range 0–15.62) 
and 1.23 (range 0–25.28 per cent) respectively in a systematic review 
of dysplasia after restorative proctocolectomy.36 Dysplasia was equally 
frequent in the pouch and rectal cuff or anal transitional zone. Dysplasia 
and cancer identified before or at operation seemed to be significant pre-
dictors of the development of pouch dysplasia. Data from this systematic 
review have been confirmed by others indicating that even if the indica-
tion for colectomy has been dysplasia or cancer, the risk of having dyspla-
sia in the rectal cuff or pouch was very low.186,187 No specific follow-up is 
therefore recommended after restorative proctocolectomy in the absence 
of risk factors.
In patients with UC, proctocolectomy with ileal pouch-anal 
anastomosis (IPAA) may be followed by signs and symptoms related 
to pouchitis (occurring in up to 50% of patients at 10years) or 
to other conditions (irritable pouch syndrome, CD of the pouch, 
ischemic pouch, cytomegalovirus, CMV or Clostridium difficile 
infection).188,189
Timing of clinical follow up is related to the development of these 
signs and symptoms in subgroups of patients, although not standard-
ized schedule is currently available. In the early postoperative period, 
patients may require liquid infusions due to watery diarrhea or elec-
trolytes imbalances, although specific timing of hematochemical 
and clinical assessment should be tailored on a patients' basis. Daily 
clinical experience suggests a clinical and routine hematochemical 
assessment (CBC, serum iron, ferritin, electrolytes, CRP, serum albu-
min and creatinin) within 3months from surgery, although earlier 
assessment may be required (EL5, RG5). Subsequent clinical evalua-
tions should be assessed on a patients' basis.
In UC patients with IPAA with signs and symptoms compatible 
with pouchitis (liquid stools, urgency, tenesmus, pelvic discomfort, 
electrolytes imbalance), pouchoscopy should be performed in order 
to discriminate between pouchitis and other conditions (irritable 
pouch, ischemic pouch, CMV or C. difficile infections, CD of the 
pouch).190 Timing of the endoscopic follow up is related to the spe-
cific indication (EL5, RG5).191
2.9.4 Adjuvant medication
Opioid analogues like loperamide are used to reduce the 
increased bowel frequency observed in patients with UC patients 
after restorative proctocolectomy with IPAA. The evidence for this 
is limited since only a few studies addressed this topic. In 1998, an 
open-label study192 aimed to assess the clinical efficacy of loperamide 
and its effect on pouch motility in 14 patients with an ileoanal res-
ervoir with parameters recorded for 24h while taking no medication 
and for 24h while receiving 8mg loperamide. Loperamide decreased 
median bowel frequency (4.0 vs 5.5; P=0.03) and 24-h stool weight 
(413g vs 610g; P=0.03) but not individual stool weights. In 2001, 
the effect of loperamide hydrochloride on bowel function was inves-
tigated in 8 patients with IPAA (8 for UC, 2 for FAP) in a blinded, 
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three-tailed, case-controlled and randomized crossover trial, using a 
daily dose of 12mg either orally (4mgt.d.s.) or as suppository (6mg 
b.d.). Mean daily stool frequency during the oral loperamide phase 
was lower than during both the placebo (P=0.05) and suppository 
(P<0.02) phases.193 In a randomized, placebo-controlled, double-
blind, crossover study the effects of loperamide versus placebo were 
investigated in 30 patients with IPAA. Findings suggested that while 
loperamide increased resting anal pressure by approximately 20% 
(P<0.05), squeeze pressure was not affected. Loperamide also did 
not appear to affect pouch volume or contractility. A reduced bowel 
frequency and an improved nighttime continence, with less soiling 
(P<0.05) and need to wear a protective pad was reported to be asso-
ciated with loperamide use.194 Cholestyramide and psyllium might 
be useful in reducing the bowel frequency and in binding the stool, 
although evidence is lacking. However, uncontrolled clinical obser-
vations suggest that cholestyramine may reduce the bowel frequency 
related to fat malabsorption, although the dose should be tailored 
on an individual basis (EL5). No standardized doses of supplements 
(Vitamin B, folate acid, iron) are available for preventing/treating 
related deficiencies in UC patients with IPAA. Indication for using 
these supplements should be assessed during the follow up of UC 
patients with IPAA. Instead of determining the levels of vitamin B 
and folate acid, patients with pouches can be advised to take these 
supplements routinely.
2.9.5 The leaking anastomosis
Subsequent restoration of continuity is often possible but with a 
risk of compromised pouch function (EL3).
No robust data exists how to treat a leaking anastomosis or pel-
vic sepsis other than transanal irrigation, percutaneous drainage or 
as last option surgery. Chronic pelvic sepsis is associated with poor 
pouch function, long term pouch failure and development of persist-
ing presacral sinus.165,166,195–197 It seems of great importance to treat 
the pelvic sepsis aggressively in order to avoid the long term seque-
lae. Recently, the Endosponge®, a low vacuum system inserted in 
the presacral cavity with the flexible endoscope has been used in the 
treatment of even near complete dehiscence of ileoanal anastomosis 
with favourable results.198–200
2.10 Special situations
2.10.1 Sexual function, fertility and delivery
UC patients have a poor sexual function and a reduced desire for 
childbearing associated with fears of disease worsening or functional 
concerns, in particular following restorative proctocolectomy, of 
which a decrease in fertility and sexual dysfunction are acknowl-
edged complications.108,201–205
The largest published series of IPAA to date reports sexual dys-
function in 1 in 7 patients, a figure similar to the reported level 
of social and work restrictions.70 Nonetheless, those patients also 
report persisting excellent quality of life and increased overall sexual 
satisfaction in a meta-analysis.201,206 Indeed, 2 prospective evalua-
tions showed an improvement in sexual function in both genders 
12months after IPAA when compared to preoperative levels.108,207 
These findings are important in overall clinical care of patients with 
UC and should be addressed when counseling patient about treat-
ment options.
Cohort studies and meta-analysis have demonstrated that open 
IPAA reduces female fecundity,208–210 most probably because of adhe-
sions affecting the fallopian tubes.211 Conversely, studies of patients 
with familial adenomatous polyposis who had an ileorectal anas-
tomosis (IRA) showed no reduction in fecundity.212,213 Half to two-
thirds of patients still live with their IRA after 20years.136,139,140 Yet, in 
IRA the retained rectum remains exposed to inflammation and to a 
residual risk of cancer that mandates surveillance.214–216 On the other 
hand, IRA does not disturb sphincter function, unlike IPAA, does 
not impair fecundity, and can be discussed as a temporizing option. 
In males, the potential complications of a pelvic procedure that are 
avoided by an IRA include retrograde ejaculation and erectile dys-
function,202 which both may make conception more problematic.
Growing evidence suggests that laparoscopic IPAA may allow 
curative surgery while limiting the negative consequences on female 
fecundity.95,96 Indeed, infertility rates after laparoscopic IPAA were 
lower than after open IPAA. This was explained by reduced pelvic 
adhesions after laparoscopic IPAA.217
A recent population based study from Sweden showed that 
women with UC and no previous surgery had a nearly 2 fold 
increased risk of an elective cesarean section,218 although a vaginal 
delivery remains the safest way for both mother and baby. Prior 
abdominal surgery increases this figure, both because of concern 
about anal continence and because an emergent cesarean section 
in face of abdominal adhesions may turn hazardous. Vaginal deliv-
ery has a 0.5–3.5% risk of inflicting significant maternal sphincter 
tears,219,220 the risk being highest at the first delivery.221 On the other 
hand, multiple deliveries have been shown to prolong pudendal 
nerve terminal motor latency.222,223 People with an IPAA have a very 
limited margin for maintaining fecal continence compared to the 
general population. This is because many factors considered impor-
tant for normal continence, such as solid stools, rectal sensation, 
and recto-anal nervous interplay are absent in people with an IPAA. 
Consequently they rely heavily on their sphincter for maintaining 
continence.
Principally on these grounds many surgeons recommend that 
their patient have a caesarian section rather than a vaginal delivery, 
translating in a cesarean section rate of 49% in a meta-analysis224 
14 T. Øresland et al.
and an unsettled controversy in the literature.188,225 Nonetheless, the 
same meta-analysis concluded that vaginal delivery appeared safe 
and did not affect anal continence, with pouch function only affected 
during the third trimester and returning to baseline within 6months 
after delivery. However, pouch function seemed to deteriorate faster 
in the long-term follow-up (beyond 5years) after vaginal delivery,226 
in particular when vaginal delivery was at high risk of obstetric 
injury (instrumental delivery, episiotomy, baby weighting more than 
4000g, emergent cesarean section, and delivery with a second stage 
of labour over 2hours).225 Hence, an informed decision about the 
mode of delivery requires a thorough discussion between the patient, 
her colorectal surgeon, and the obstetrician weighting in risk factors, 
patient's values, and elements of the literature.
2.10.2 Perianal problems
The real incidence of perianal problems in patients with UC is 
not clearly quantified. In the past, the overall perianal complications 
rate was reported in the range of 3.7% to 32%, considering all “ano-
rectal complications” (including haemorrhoids, skin tags, anal stric-
tures, etc.). However, these rates were misleading because colonic 
Crohn's disease (CD) and Indeterminate Colitis (IC) were first rec-
ognized in the 1960s and 1970s respectively.227 Since improper sur-
gical management of haemorrhoids and anal fissure may affect anal 
sphincter mechanism and the possibility of performing an adequate 
ileo-anal anastomosis, the treatment should be as conservative as 
possible. When necessary, surgery should be performed by a colorec-
tal surgeon aware of IPAA procedure.227 Recent reports have shown 
an incidence of perianal disease, namely abscesses and fistulas, in UC 
population of 5%, and in surgical UC series of 7%.228,229 In a recent 
case–control study on 758 UC patients, Zabana et  al. found that 
70% who developed perianal disease did not meet diagnostic criteria 
of CD, despite diagnostic reassessment. Perianal disease was more 
frequent in men (62%) and it was associated with a more aggres-
sive disease, requiring steroids, immunomodulators and biological 
treatments. These patients seem to have a higher hospitalization and 
colectomy rates.229
Since different diagnostic and therapeutic options are available 
for the treatment of perianal disease, a general approach should be 
followed through adequate control of sepsis (abscess drainage and 
seton placement), sphincter preservation, low damage to anal and 
perianal tissues, evaluation of mucosal inflammation, and differen-
tial diagnosis with CD. Once the diagnosis of CD is excluded, there 
are no controlled data on medical and surgical management of peri-
anal disease in UC. The Consensus agreed that if the inflammation 
of the rectum is absent or mild, diagnostic and surgical ECCO guide-
lines for perianal Crohn's Disease should be used.189 In the presence 
of perianal fistulas and/or abscesses with moderate or severe UC 
activity, the simultaneous control of both sepsis and inflammation is 
mandatory. ECCO guidelines for the medical treatment of Ulcerative 
Colitis should be followed.6 In the presence of an abscess at clini-
cal examination, the drainage should be performed before any other 
diagnostic procedure. Uncontrolled perianal sepsis in UC patients 
under steroids and/or immunosuppressant treatment can lead to 
Fournier's gangrene, a rapidly progressive, life threatening condi-
tion that require emergency surgery.230 Contrast-enhanced MRI 
should be the initial procedure for the study of perianal UC, since 
it gives additional information on rectal and perirectal structures; 
Endoscopic Ultrasound (EUS) has similar sensitivity, but inferior 
specificity than MRI, and it cannot be performed in the presence 
of stenosis and painful abscesses; Transperineal Ultrasound (TPUS) 
could be used in the presence of anal stenosis or abscesses231; US 
methods can be improved with hydrogen peroxide enhancement; 
Computed Tomography (CT) is preferred in emergency settings. 
Fistulography is no more recommended. All these methods achieve 
the best results when combined with examination under anaesthetics 
(EUA). EUA is reported to have an accuracy of 90% in the hands of 
an experienced colorectal surgeon, but most important, it permits 
contemporary identification of all fistulae tracts, loose seton posi-
tioning, and abscess drainage.189 Simple perianal fistulae should be 
treated, only if symptomatic, with loose seton placement and anti-
biotics (metronidazole and ciprofloxacin). Complex fistulae should 
always be treated by abscess drainage and loose seton placement. 
Concomitant luminal disease should be treated with antibiotics, a 
combination of topical and oral compounds, immunomodulators or 
biologicals when appropriate, depending on extension and severity 
of the inflammation.6
Since perianal disease seems to be associated with a more 
aggressive disease course, some of these patients will finally require 
colectomy.227,229 In case of IPAA is needed, a prior perianal disease 
increases the risk of developing an ileoanal anastomotic leak and 
postoperative perianal complications,228 and it is an independent 
negative predictor of long-term pouch survival.228,232 In selected 
and well informed patients, with previously healed perianal disease, 
IPAA should be performed with a temporary diverting ileostomy.227
2.10.3 Colorectal Cancer
In the past, almost 10% of UC patients who underwent resection 
were found to have a colorectal cancer (CRC) in the specimen.233 
Eaden et al., in a meta-analysis on 116 studies, reported an overall 
incidence of CRC in UC of 3.7%, increasing to 5.4% in the presence 
of pancolitis. The cumulative risk of CRC was reported to be of 2% 
at 10years, 8% at 20years, and 18% at 30years.22 A systemic review 
by Bernstein reported 42% of patients with high-grade dysplasia 
and 43% of patients with DALM having a synchronous CRC at 
immediate colectomy.24 In a recent series form the Cleveland Clinic, 
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synchronous dysplasia or cancer in the specimen of patients with 
preoperative diagnosis was 48% and 12% respectively.234 Strictures 
associated to even low-grade dysplasia are malignant in 20%-24% 
of the cases.235 A consistent number of patients (11.7%), having a 
colectomy for dysplasia or cancer and found to have a CRC in the 
operative specimen, had Dukes' C or D postoperative staging.27 Due 
to the high risk of multiple tumor locations and preoperative under 
staging, total proctocolectomy for dysplasia or cancer should be per-
formed with adequate lymph nodes removal in all colonic segments. 
However, there are some technical implications in these settings. 
Patients with CRC of the ascending colon should receive adequate 
oncologic operation with removal of the terminal ileum, ileo-colonic 
vessels ligation, and regional lymph nodes excision, so they have 
to be informed about the diminished possibility of performing an 
adequate IPAA. Patients with dysplasia or cancer in any colonic seg-
ment, but with negative rectal biopsies and a rectum which can be 
easily examined, should receive a more conservative procedure with 
Denonviller's fascia preservation and an accurate “nerve sparing” 
procedure.
The role of restorative proctocolectomy in the setting of UC com-
plicated by rectal adenocarcinoma is unclear. Main oncologic con-
cerns are that an active UC treated by radio and/or chemotherapy 
in neo-adjuvant setting may complicate with massive bleeding236; 
the presence of the pouch could interfere with the administration of 
chemotherapy; and postoperative radiotherapy could compromise 
the integrity of the pouch. Post operative pelvic radiotherapy can 
be associated with worse functional outcomes when administered 
for those who have had an anterior resection for rectal cancer.237 
Similar effects may be seen in the setting of an ileoanal pouch. Taylor 
et al. in their series of patients with familial adenomatous polyposis 
suggested that advanced rectal cancer treated with adjuvant radio-
therapy may be associated with worse function.238 Remzi et al. have 
suggested that radiotherapy should not be used post operatively even 
if the diagnosis of rectal cancer is made after surgery.239 In the situ-
ation where inflammatory disease activity is absent the best option 
for patients needing radiotherapy is to receive it in the neo-adjuvant 
setting. On the contrary, pouch radiation inevitably lead to pouch 
failure. Another option should be a staged procedure with radiation 
following a subtotal colectomy with Hartman's closure and ileos-
tomy. In general, radiation treatment is associated with an elevated 
risk of pouch failure (16% vs 7%), but the oncologic outcome do 
not seems to be affected.240–243
Patients requiring surgery for colorectal cancer who might 
require adjuvant therapy need careful consideration. Preoperative 
staging may prove inaccurate and in order to reduce side effects 
of any adjuvant therapy on pouch function, a staged procedure 
should be performed.240,241,243 In fact, adjuvant therapy cessation 
for pouch related intolerance could worsen cancer prognosis, 
while adjuvant therapies could adversely influence pouch func-
tion.240 Patients with CRC and a reliable preoperative clinical 
Stage I  or II (in particular rectal cancer that seems to be easier 
staged) should be treated with restorative proctocolectomy with 
or without diverting ileostomy.242 UC patients treated with IPAA 
and needing post-operative adjuvant therapy should receive stand-
ard dosage of chemotherapeutic agents. The risk of diarrhea asso-
ciated with chemotherapy for colorectal cancer is estimated to be 
as high as 82%. A third of these patients usually experience grade 
III or IV diarrhea.244 Specific data on this topic are absent, but 
IBD patients seem to be at higher risk for developing severe diar-
rhea during chemotherapy, due to the toxic effects of cytotoxic 
drugs or a flare of the IBD itself. A regimen of continuous infu-
sional 5-FU alone, in combination with leucovorin, or in combina-
tion with oxaliplatin should be best tolerated. Bolus infusions of 
5-FU and combination therapy of irinotecan with 5-FU should be 
avoided because of severe diarrhea and the possibility of sepsis. 
Diarrhea should be empirically treated with aminosalicylates.236 In 
the presence of an ileostomy or an ileoanal pouch, diarrhoea may 
be severe enough to need modification of chemotherapy dosing.
2.10.4 Surgery for pouchitis and cuffitis
The diagnosis of pouchitis requires the presence of symptoms, 
together with endoscopic and histological abnormalities. Extensive 
UC, extraintestinal manifestations, being a non-smoker, p-ANCA 
positive serology and NSAID use are possible risk factors for 
pouchitis. The most frequent symptoms of pouchitis are increased 
number of liquid stools, urgency, abdominal cramping and pelvic 
discomfort. Fever and bleeding are rarely present. The majority 
of patients respond to metronidazole or ciprofloxacin, although 
the optimum modality of treatment is not clearly defined. Anti-
diarrhoeal drugs may reduce the number of daily liquid stools, 
independently of pouchitis. In chronic pouchitis a combination of 
two antibiotics is effective, and oral budesonide is an alternative. 
Infliximab should be effective for the treatment of chronic refrac-
tory pouchitis. Probiotic therapy with VSL#3 has shown efficacy 
for maintaining antibiotic-induced remission and for preventing 
pouchitis.189
For patients who have persistent symptoms, alternative diagnoses 
should be considered, including undiagnosed Crohn's disease, pouch-
anal or ileal-pouch stricture, infection with CMV or Clostridium 
difficile, collagenous pouchitis, cuffitis, anatomical disorders, or irri-
table pouch syndrome. Approximately 10-15% of patients with acute 
pouchitis develop chronic pouchitis.226,245–247 Patients with chronic, 
refractory pouchitis do not respond to conventional therapy and often 
have on-going symptoms. This refractory condition may ultimately be 
a cause of pouch failure. In large institutional series, the risk of pouch 
failure is about 10% at 10years and chronic pouchitis accounts for 
10% of the failures. Little data exist to help decide between excluding 
or excising a failed pouch. What data there is suggests that excision 
may confer a better outcome in terms of quality of life.140,170,248–251
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Cuffitis can cause pouch dysfunction with symptoms that mimic 
pouchitis or irritable pouch syndrome (IPS), especially after double-
stapled IPAA. A coexisting pouch disorder should be excluded, but 
bleeding is a characteristic feature of cuffitis. Endoscopy is diag-
nostic and care has to be taken to examine the cuff of columnar 
epithelium between the dentate line and pouch-anal anastomosis. 
In an open-label trial, 14 consecutive patients with cuffitis treated 
with mesalazine suppositories 500mg twice daily experienced a 
reduction in the total Cuffitis Activity Index (derived from the 
PDAI). Symptom, endoscopy, and histology scores were signifi-
cantly reduced. 92% of patients with bloody bowel movements and 
70% with arthralgia improved after therapy.188,190 The symptoms 
of retained rectal mucosa are those of proctitis, including bleeding, 
burning and urgency, with frequent passage of small amounts of 
stool. These patients are at risk of neoplastic transformation.252–254 In 
a series of 217 patients with stapled IPAA an inflamed mucosa distal 
to the anastomosis was present in 22% of the patients, and retreat-
ment was needed in 13%.255 Tulchinsky et al. reported a series of 
22 patients submitted to major revisional surgery for retained rectal 
stump with a successful rate of 68%.248
2.10.5 Non inflammatory pouch dysfunction and pouch failure
Definition: Failure of the pouch is defined as the excision of the 
pouch or indefinite defunctioning.
Definition: Redo ileal pouch-anal anastomosis (IPAA) is defined 
as an operation for malfunctioning pouch or pelvic septic complica-
tions, with pelvic dissection, pouch disconnection, pouch revision, 
reconstruction or advancement, and reanastomosis.
There are no randomised trials to ascertain the best surgical pro-
cedure for UC. Despite this limitation there are many retrospective 
series and prospective observational studies from tertiary centres to 
determine outcomes from surgery for UC. Reliable data from over 
9.000 patients have been reported to date.256 Overall pouch fail-
ure is reported to range from 0,5% to 24% of cases; the frequency 
increases over time, reaching the higher values during long-term fol-
low-up.252,256 Postoperative pelvic sepsis ranges from 2.5% to 26.7% 
and acute and chronic septic complications, such as fistulas and 
sinuses, account for 50% to 65% of the causes for pouch removal. 
Poor pouch function due to mechanical outlet obstruction accounts 
for 35% to 55% of pouch excisions. Different techniques for pouch 
construction (e.g. “J” vs “S” shape) and ileo-anal anastomosis (e.g. 
hand-sewn vs stapled) are reported to have different and specific 
complications. The main complications are anastomotic strictures, 
afferent and efferent limb problems, retained rectum, and small 
reservoir. Chronic inflammations of the pouch or the cuff and neo-
plastic transformation are the cause of pouch removal in 5-10% of 
the cases. Pouch prolapse, pouch intussusception, mega-pouch, irri-
table pouch syndrome, anismus and sphincter dysfunctions, are rare 
conditions, responsible for 2-3% of redo IPAA surgery.15,196,257–262
Since IPAA surgery is not only an anatomical reconstruction, 
but also a “quality of life” intervention, the first step in the diag-
nosis of pouch disorders is a careful clinical history and examina-
tion. This can guide the clinician to discriminate the nature of the 
problem (s) affecting the pouch and to design the adequate diag-
nostic workup. Endoscopy is essential in order to obtain informa-
tion on the mucosa status, such as cuffitis, pouchitis, and Crohn's 
disease. Both endoscopy and pouch enema are useful for evaluation 
of pouch distensibility, afferent and efferent limb disorders, mucosal 
prolapse, and pouch torsion. Essential for most disorders is to obtain 
2D/3D imaging through a tomographic device. Computed tomogra-
phy (CT), magnetic resonance imaging (MRI), and ultrasonography 
(either endoanal or transperineal) are very sensitive to identify and 
characterize septic problems and most of mechanical disorders.231 
Unfortunately, no diagnostic tools are available to discriminate the 
presence of fibrosis.196,263–265 As proposed in the ECCO indications 
for perianal Crohn's disease, in case of fistulas, abscesses, sinuses, 
and IPAA stenosis, examination under anaesthesia (EUA) is very 
important for diagnosis and contemporary treatment of most condi-
tions. The association of EUA, performed by an experienced IBD 
surgeon, together with one of the tomographic imaging devices (CT, 
MRI, US) give the best levels of accuracy.189
A large proportion of patients who experience postoperative 
pouch problems are successfully treated by transanal approach, 
with or without faecal diversion. Transanal resolution of IPAA ste-
nosis by dilation is effective in 45% to 95% of the cases, but often, 
more than one procedure is necessary to obtain satisfactory results. 
The most important prognostic factor for the success of the dila-
tion is absence of fibrosis. Septic complications are also managed by 
EUA, especially where abscess drainage, simple perianal fistulas and 
sinuses are concerned. Fistulotomy, fistulectomy, loose seton place-
ment, sphincterotomy and pouch-flap advancement are all feasible 
for the treatment of post-pouch complications. Multiple and/or com-
plicated perianal fistulas, large pre-sacral sinuses, as well as pouch-
vaginal fistulas often need a temporary ileostomy for prolonged 
periods.196,248,257,261,266,267
Redo pouch is necessary when the IPAA has to be disconnected 
and the pouch revised or reconstructed through a combined transab-
dominal and transperineal approach. Identification of the precise 
pouch dysfunction is mandatory in order to optimize surgical strat-
egy. In general, indications for pouch revision can be divided in 
mechanical and infectious or inflammatory. Mechanical causes of 
malfunctioning may be identified such as a stenosis of IPAA, an effer-
ent limb that is too long in an “S” pouch, a blind limb of a “J” pouch 
which is too long, kinking of the afferent limb, twisting of the pouch, 
pouch intussusception, small pouch volume, megapouch, and a long 
rectal stump. Ideally, obstructing problems should be managed using 
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the existing pouch by disconnection of the IPAA and redo transanal 
handsewn anastomosis, while for volume problems specific proce-
dures have been proposed in order to reduce or enlarge the volume 
of the pouch. Septic complications require more often a complete 
reconstruction because the pouch itself is frequently involved. 
Inflammatory disorders, such as chronic refractory pouchitis and 
Crohn's disease should be managed by aggressive medical treat-
ment, and in case of failure a permanent ileostomy may be necessary. 
Cuffitis may need a complete mucosectomy and handsewn anasto-
mosis, whether through transanal or combined access.52,141,196,248,256–271 
In general, redo pouch surgery seems to have better results when 
performed for mechanical than for septic complications. When per-
formed by experienced surgeons in tertiary centres, redo pouch is a 
safe and effective procedure. More than 600 patients are reported 
in the literature to undergo salvage surgery for pouch failure, with 
no mortality rate and a perioperative complication rate that ranges 
from 19% to 51%. The outcomes after revisional surgery are also 
encouraging, having a salvage rates ranging from 50% to 100%. In 
those studies with a 5-years follow-up or longer, the pouch survival 
was estimated between 75% and 85%. Even if measured with dif-
ferent methods, the Quality of Life (QoL) after revisional pouch sur-
gery has been assessed by several Centres and the results are reported 
as satisfactory from 50% to 93% of the patients.141,257,260,267,271 Both 
in terms of postoperative complications and functional results there 
is a trend among authors in favour of preserving the existing pouch 
versus reconstruction and in case of an indication for mechanical 
problems versus septic complications.52,141,201,248,261,262,266–269
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